Invitation to presentation of BioInvent's second quarter report 2020 on August 27, 2020

Rhea-AI Summary

BioInvent International AB (OMXS: BINV) will release its interim report for Q2 2020 on August 27 at 8:00 a.m. CEST. This will be followed by an audiocast and teleconference at 5:30 p.m. CEST, led by CEO Martin Welschof and the management team. Participants can join via phone or webcast. BioInvent is focused on developing immuno-modulatory antibodies for cancer treatments, with ongoing clinical programs and a proprietary technology platform. Further details are available on their website.

LUND, Sweden, Aug. 21, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2020 on Thursday August 27 at 8.00 a.m. CEST, followed by an audiocast with teleconference at 5.30 p.m. CEST, hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English.

To participate, please call any of the following phone numbers from:

SE: +46 850558350

NE: +31 107129163

UK: +44 3333009266

US: +1 8335268398

Webcast: https://tv.streamfabriken.com/bioinvent-q2-2020

About BioInvent

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:

Martin Welschof, CEO	Hans Herklots, LifeSci Advisors
+46 (0)46 286 85 50	+41 79 598 71 49
martin.welschof@bioinvent.com	hherklots@lifesciadvisors.com

BioInvent International AB (publ)

Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

www.bioinvent.com  

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

https://mb.cision.com/Main/583/3177602/1295401.pdf

Press release (PDF)

View original content:http://www.prnewswire.com/news-releases/invitation-to-presentation-of-bioinvents-second-quarter-report-2020-on-august-27-2020-301116275.html

SOURCE BioInvent

FAQ

When will BioInvent release its Q2 2020 interim report?

BioInvent will release its Q2 2020 interim report on August 27, 2020, at 8:00 a.m. CEST.

What time is the audiocast for BioInvent's Q2 report?

The audiocast for BioInvent's Q2 report will take place on August 27, 2020, at 5:30 p.m. CEST.

How can I participate in BioInvent's report presentation?

You can participate by calling specific phone numbers or joining the webcast available at BioInvent's website.

What is BioInvent's main focus regarding drug development?

BioInvent develops novel immuno-modulatory antibodies for cancer therapies.

What technology platform does BioInvent utilize?

BioInvent uses the proprietary F.I.R.S.T™ technology platform to identify targets and antibodies.